Comment: The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations

The Lancet Global Health
Oct 2013  Volume 1  Number 4  e169 – 237
http://www.thelancet.com/journals/langlo/issue/current

Comment
The Global Health Innovative Technology (GHIT) Fund: financing medical innovations for neglected populations
BT Slingsby, Kiyoshi Kurokawa

Preview |
The newly launched Global Health Innovative Technology (GHIT) Fund, which is multisectoral, interdisciplinary, and not for profit, aims to expedite the generation of novel medical technologies and drugs to diagnose, prevent, and treat high-prevalence infectious diseases worldwide. The GHIT Fund represents the first public–private partnership to involve a national government, a UN agency, a consortium of pharmaceutical companies, and an international philanthropic foundation (founding partners are the Japanese Ministry of Foreign Affairs; the Japanese Ministry of Health, Labour and Welfare; the UN Development Programme; Astellas Pharma; Daiichi Sankyo Company; Eisai Company; Shionogi & Company; Takeda; and the Bill & Melinda Gates Foundation).